61
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Leveraging Selective Knockdown of Sost Gene by Polyethyleneimine–siRNA–Chitosan Reduced Gold Nanoparticles to Promote Osteogenesis in MC3T3-E1 & MEF Cells

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 895-914 | Received 08 Nov 2023, Accepted 30 Jan 2024, Published online: 26 Mar 2024

References

  • Rachner TD , KhoslaS , HofbauerLC. Osteoporosis: now and the future. Lancet377(9773), 1276–1287 (2011).
  • Qiao D , LiuX , TuRet al. Gender-specific prevalence and influencing factors of osteopenia and osteoporosis in Chinese rural population: the Henan Rural Cohort Study. BMJ Open10(1), e028593 (2020).
  • Kanis JA , McCloskeyEV , JohanssonHet al. A reference standard for the description of osteoporosis. Bone42, 467–475 (2008).
  • Duan P , BonewaldLF. The role of the Wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth. Int. J. Biochem. Cell Biol.77, 23–29 (2016).
  • Wang Y , LiYP , PaulsonCet al. Wnt and the Wnt signaling pathway in bone development and disease. Front. Biosci. Landmark Ed.19, 379–407 (2014).
  • Lewiecki EM . Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther. Adv. Musculoskelet. Dis.6(2), 48–57 (2014).
  • Rauner M , TaipaleenmäkiH , TsourdiEet al. Osteoporosis treatment with anti-sclerostin antibodies-mechanisms of action and clinical application. J. Clin. Med.10(4), 787 (2021).
  • Sedaghati B , JahroomishiraziR , StarkeAet al. Rat osteosarcoma cells as a therapeutic target model for osteoregeneration via sclerostin knockdown. Cells Tissues Organs201(5), 366–379 (2016).
  • Traber GM , YuAM. RNAi-based therapeutics and novel RNA bioengineering technologies. J. Pharmacol. Exp. Ther.384(1), 133–154 (2023).
  • Delgado-Calle J , SatoAY , BellidoT. Role and mechanism of action of sclerostin in bone. Bone96, 29–37 (2017).
  • Aryana IGPS , RiniSS , SoejonoCH. Importance of sclerostin as bone-muscle mediator crosstalk. Ann. Geriatr. Med. Res.26(2), 72 (2022).
  • Ozcan G , OzpolatB , ColemanRLet al. Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Deliv. Rev.87, 108–119 (2015).
  • Tokatlian T , SeguraT. siRNA applications in nanomedicine. WIREs Nanomed. Nanobiotechnol.2, 305–315 (2010).
  • Zhang G , GuoB , WuHet al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat. Med.18, 307–314 (2012).
  • Basha G , OrdobadiM , ScottWRet al. Lipid nanoparticle delivery of siRNA to osteocytes leads to effective silencing of SOST and inhibition of sclerostin in vivo. Mol. Ther. Nucleic Acids5(9), e363 (2016).
  • Liu X . Bone site-specific delivery of siRNA. J. Biomed. Res.30(4), 264–271 (2016).
  • Shen J , KimHC , MuCEet al. Multifunctional gold nanorods for siRNA gene silencing and photothermal therapy. Adv. Healthcare Mater.3, 1629–1637 (2014).
  • Tan WB , ZhangY. Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications. J. Biomed. Mater. Res. A75, 56–62 (2005).
  • Yang Z , LiuT , XieYet al. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer. Acta Biomater.25, 194–204 (2015).
  • Labala S , JoseA , VenugantiVV. Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma. Colloids Surf. B146, 188–197 (2016).
  • Mora-Raimundo P , LozanoD , ManzanoMet al. Nanoparticles to knockdown osteoporosis-related gene and promote osteogenic marker expression for osteoporosis treatment. ACS Nano13(5), 5451–5464 (2019).
  • Boca SC , PotaraM , ToderasFet al. Uptake and biological effects of chitosan-capped gold nanoparticles on Chinese hamster ovary cells. Mater. Sci. Eng. C31, 184–189 (2011).
  • Bhumkar DR , JoshiHM , SastryMet al. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharmacol. Res.24, 1415–1426 (2007).
  • Shen J , KimHC , SuHFet al. Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics4(5), 487–497 (2014).
  • Jeong S , ChoiSY , ParkJet al. Low-toxicity chitosan gold nanoparticles for small hairpin RNA delivery in human lung adenocarcinoma cells. J. Mater. Chem.21(36), 13853–13859 (2011).
  • Sharma K , SomavarapuS , ColombaniAet al. Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery. Int. J. Pharm.455(1–2), 241–247 (2013).
  • Hoemann CD , El-GabalawyH , McKeeMD. In vitro osteogenesis assays: influence of the primary cell source on alkaline phosphatase activity and mineralization. Pathol. Biol.57(4), 318–323 (2009).
  • Hong D , ChenHX , YuHQet al. Morphological and proteomic analysis of early stage of osteoblast differentiation in osteoblastic progenitor cells. Exp. Cell Res.316(14), 2291–2300 (2010).
  • Saito M , SaitohH. Labeling of polyethylenimine with fluorescent dye to image nucleus, nucleolus, and chromosomes in digitonin-permeabilized HeLa cells. Biosci. Biotechnol. Biochem.76(9), 1777–1780 (2012).
  • Han L , ZhaoJ , ZhangXet al. Enhanced siRNA delivery and silencing gold-chitosan nanosystem with surface charge-reversal polymer assembly and good biocompatibility. ACS Nano.6(8), 7340–7351 (2012).
  • Tümay S , LaleO , BaşaranNC. An overview and management of osteoporosis. Eur. J. Rheumatol.4(1), 46–56 (2017).
  • Serrano-Sevilla I , ArtigaÁ , MitchellSGet al. Natural polysaccharides for siRNA delivery: nanocarriers based on chitosan, hyaluronic acid, and their derivatives. MOLEFW24(14), 2570 (2019).
  • Raval N , JogiH , GondaliyaPet al. Method and its composition for encapsulation, stabilization, and delivery of siRNA in anionic polymeric nanoplex: an in vitro-in vivo assessment. Sci. Rep.9, 16047 (2019).
  • Wang D , ChristensenK , ChawlaKet al. Isolation and characterization of mc3t3 e1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res.14, 14893–14903 (1999).
  • Matsuoka F , TakeuchiI , AgataHet al. Morphology-based prediction of osteogenic differentiation potential of human mesenchymal stem cells. PLOS ONE8(2), e55082 (2013).
  • Lew KS , OthmanR , IshikawaKet al. Macroporous bioceramics: a remarkable material for bone regeneration. J. Biomater. Appl.27, 3452358 (2012).
  • Quarles LD , YohayDA , LeverLWet al. Distinct proliferative and differentiated stages of murine MC3T3-e1 cells in culture: an in vitro model of osteoblast development. J. Bone Miner. Res.7, 683–692 (2009).
  • Sawa N , FujimotoH , SawaYet al. Alternating differentiation and dedifferentiation between mature osteoblasts and osteocytes. Sci. Rep.9, 13842 (2019).
  • Liang C , GuoB , WuHet al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat. Med.21, 288–294 (2015).
  • Komori T . Regulation of osteoblast differentiation by runx2. Adv. Exp. Med. Biol.65, 843–849 (2010).
  • Zhang ZH , JiaXY , FangJYet al. Reduction of SOST gene promotes bone formation through the Wnt/β-catenin signalling pathway and compensates particle-induced osteolysis. J. Cell Mol. Med.24, 4233–4244 (2020).
  • Kim Y-J , LeeM-H , WozneyJMet al. Bone morphogenetic protein-2-induced alkaline phosphatase expression is stimulated by dlx5 and repressed by msx2. JF Biol. Chem.279, 50773–50780 (2004).
  • Franceshi RT , IyerBS. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-e1 cells. J. Bone Miner. Res.7, 235–246 (1992).
  • Ismail F , EpsteinS , PacificiRet al. Serum bone gla protein (BGP) and other markers of bone mineral metabolism in postmenopausal osteoporosis. Calcif. Tissue Int.39(4), 230–233 (1986).
  • Kanazawa I , YamaguchiT , YamamotoMet al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.94, 45–49 (2009).
  • Nakamura-Ota M , HamanakaR , YanoHet al. A new murine osteoblastic cell line immortalized with the sv40 large T antigen. Cell Tissue Bank15, 373–380 (2013).
  • Zakeri A , KouhbananiMAJ , BeheshtkhooNet al. Polyethylenimine-based nanocarriers in co-delivery of drug and gene: a developing horizon. Nano Rev. Experim.9(1), 1488497 (2018).
  • Behzadi S , SerpooshanV , TaoWet al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev.46(14), 4218–4244 (2017).
  • Verma AK , SachinK , SaxenaAet al. Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor-cycloheximide, for possible therapeutic applications. Curr. Pharm. Biotechnol.6(2), 121–130 (2005).
  • Verma AK , ChanchalA , ChutaniK. Augmentation of anti-tumour activity of cisplatin by pectin nano-conjugates in B-16 mouse model: pharmacokinetics and in-vivo biodistribution of radio-labelled, hydrophilic nano-conjugates. Int. J. Nanotechnol.9(10–12), 872–886 (2012).
  • Chaves Neto AH , MachadoD , YanoCLet al. Antioxidant defense and apoptotic effectors in ascorbic acid and β-glycerophosphate-induced osteoblastic differentiation. Dev. Growth Differ.53(1), 88–96 (2011).
  • Nian F , QianY , XuFet al. LDHA promotes osteoblast differentiation through histone lactylation. Biochem. Biophys. Res. Commun.615, 31–35 (2022).
  • Hikiji H , ShinWS , OidaSet al. Direct action of nitric oxide on osteoblastic differentiation. FEBS Lett.410(2–3), 238–242 (1997).
  • Nacar MC , YigitS. Lack of association of superoxide dismutase I/D variant with osteopenia/osteoporosis in Turkish postmenopausal women. Nucleos Nucleot. Nucl.42(9), 671–682 (2023).
  • Romagnoli C , MarcucciG , FavilliFet al. Role of GSH/GSSG redox couple in osteogenic activity and osteoclastogenic markers of human osteoblast-like Sa OS-2 cells. FEBS J.280(3), 867–879 (2013).
  • Biswas L , NiveriaK , VermaAK. Paradoxical role of reactive oxygen species in bone remodelling: implications in osteoporosis and possible nanotherapeutic interventions. Exploration3, 393–413 (2022).
  • Yashiro M , OhyaM , MimaT. Active vitamin D and vitamin D analogs stimulate fibroblast growth factor 23 production in osteocyte-like cells via the vitamin D receptor. J. Pharm. Biomed. Anal.182, 113139 (2020).
  • Kim J , KigamiH , AdachiT. Comparative gene expression analysis for pre-osteoblast MC3T3-E1 cells under non-adhesive culture toward osteocyte differentiation. J. Biosci. Bioeng.132(6), 651–656 (2021).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.